Tattiya Kantasa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tattiya Kantasa has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Kankanit Yeerong
Department of Pharmacology, Faculty of Medicine Chiang Mai University Chiang Mai Thailand
2 shared publications- Mingkwan Na Takuathung
Clinical Research Center for Food and Herbal Product Trials and Development (CR-FAH), Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
2 shared publications - Nut Koonrungsesomboon
Clinical Research Center for Food and Herbal Product Trials and Development (CR-FAH), Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
2 shared publications Chadarat Ampasavate
Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, 50200, Thailand
1 shared publicationJakkrit Aisara
Department of Pharmacology, Faculty of Medicine Chiang Mai University Chiang Mai Thailand
1 shared publicationJeeraporn Chitphan
Department of Pharmacology, Faculty of Medicine Chiang Mai University Chiang Mai Thailand
1 shared publication
Latest Publications
- Open Access
- 21 January 2026
- Published by Wiley in Skin Research and Technology
- Vol. 32 (1) , e70310
A Randomized Controlled Trial of the Genistein Plus Bakuchiol and Vitamins (GEN + ) Product for Male Facial Skin: Effects on Skin Appearance and Properties
Background: With increasing life expectancy, the aging population, particularly in Asia, is expanding rapidly. Combined with intense year‐round ultraviolet exposure, this accelerates skin aging. Male skin also exhibits distinct aging characteristics. This study aims to evaluate the efficacy and safety of the Genistein Plus Bakuchiol and Vitamins (GEN + ) product on male facial skin. Materials and Methods: A randomized, double‐blind, placebo‐controlled trial was conducted in men aged 45–65 years. Participants were assigned to receive either the GEN + or placebo (PLA) product in a 1:1 ratio and applied the product twice daily for 12 weeks. Facial skin assessments were performed at baseline and at weeks 4, 8, and 12. Evaluated parameters included skin color and consistency, spots, pigmentation, redness, acne, elasticity, hydration, barrier function, and wrinkles. Compliance and satisfaction were also monitored. Results: Eighty male participants were enrolled (GEN + : n = 40; PLA: n = 40). After 12 weeks, the GEN + group demonstrated significant improvements in cheek skin lightening (MD = 0.55, 95% CI: 0.03 to 1.08, p = 0.04) and color consistency (MD = –0.56, 95% CI: –1.06 to –0.06, p = 0.03), along with a reduction in forehead spots (MD = –0.60, 95% CI: –1.15 to –0.06, p = 0.03). No significant differences were observed in melanin‐, erythema‐, or acne‐related parameters. Skin property parameters did not differ significantly between groups, except for skin roughness. Adverse events were mild and self‐resolving. While satisfaction scores did not differ significantly, the GEN + group reported higher scores across most domains. Conclusion: The GEN + product demonstrated promising improvements in male facial skin appearance, including skin lightening, color consistency, and spot reduction. The product was well‐tolerated and offered a safe, targeted skincare solution for men. Trial Registration: ClinicalTrials.gov identifier: TCTR20240312001
- 21 January 2026
- Published by Wiley in Skin Research and Technology
- Vol. 32 (1) , e70310
Open AccessA Randomized Controlled Trial of the Genistein Plus Bakuchiol and Vitamins (GEN + ) Product for Male Facial Skin: Effects on Skin Appearance and Properties
Background: With increasing life expectancy, the aging population, particularly in Asia, is expanding rapidly. Combined with intense year‐round ultraviolet exposure, this accelerates skin aging. Male skin also exhibits distinct aging characteristics. This study aims to evaluate the efficacy and safety of the Genistein Plus Bakuchiol and Vitamins (GEN + ) product on male facial skin. Materials and Methods: A randomized, double‐blind, placebo‐controlled trial was conducted in men aged 45–65 years. Participants were assigned to receive either the GEN + or placebo (PLA) product in a 1:1 ratio and applied the product twice daily for 12 weeks. Facial skin assessments were performed at baseline and at weeks 4, 8, and 12. Evaluated parameters included skin color and consistency, spots, pigmentation, redness, acne, elasticity, hydration, barrier function, and wrinkles. Compliance and satisfaction were also monitored. Results: Eighty male participants were enrolled (GEN + : n = 40; PLA: n = 40). After 12 weeks, the GEN + group demonstrated significant improvements in cheek skin lightening (MD = 0.55, 95% CI: 0.03 to 1.08, p = 0.04) and color consistency (MD = –0.56, 95% CI: –1.06 to –0.06, p = 0.03), along with a reduction in forehead spots (MD = –0.60, 95% CI: –1.15 to –0.06, p = 0.03). No significant differences were observed in melanin‐, erythema‐, or acne‐related parameters. Skin property parameters did not differ significantly between groups, except for skin roughness. Adverse events were mild and self‐resolving. While satisfaction scores did not differ significantly, the GEN + group reported higher scores across most domains. Conclusion: The GEN + product demonstrated promising improvements in male facial skin appearance, including skin lightening, color consistency, and spot reduction. The product was well‐tolerated and offered a safe, targeted skincare solution for men. Trial Registration: ClinicalTrials.gov identifier: TCTR20240312001
- Open Access
- 1 June 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 5387-5414
Therapeutic Potential of Curcumin and Novel Formulations in Psoriasis Treatment: Evidence and Future Prospects
Psoriasis is a chronic inflammatory skin disease characterized by thickened, erythematous, and scaly plaques that significantly impact patients’ quality of life. Although various treatments are available, they often cause adverse effects, prompting the exploration of alternative therapies. Curcumin, a bioactive compound in Curcuma longa Linn. (turmeric), has demonstrated potential benefits in managing psoriasis. This article aims to comprehensively evaluate the anti-psoriatic activity, efficacy, and safety profiles of curcumin and its novel formulations, as well as to discuss future directions for enhancing their use as an alternative treatment for psoriasis. Curcumin exerts its anti-psoriatic effects through multi-targeted actions, including inhibiting cell proliferation, inducing apoptosis, suppressing pro-inflammatory cytokines, and enhancing skin barrier proteins, thereby alleviating psoriasis lesions. However, both oral and topical curcumin formulations face challenges, such as low bioavailability and limited skin penetration, underscoring the need for novel formulations to improve therapeutic outcomes. Clinical findings suggest that oral curcumin may provide greater efficacy and better tolerance as an adjunctive therapy for moderate to severe psoriasis, while topical formulations may help reduce severity and improve well-being in mild to moderate cases. Overall, curcumin and its novel formulations show promise as therapeutic agents for psoriasis treatment. However, further research, particularly large-scale clinical trials, is essential to evaluate long-term efficacy and safety comprehensively.
- 1 June 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 5387-5414
Open AccessTherapeutic Potential of Curcumin and Novel Formulations in Psoriasis Treatment: Evidence and Future Prospects
Psoriasis is a chronic inflammatory skin disease characterized by thickened, erythematous, and scaly plaques that significantly impact patients’ quality of life. Although various treatments are available, they often cause adverse effects, prompting the exploration of alternative therapies. Curcumin, a bioactive compound in Curcuma longa Linn. (turmeric), has demonstrated potential benefits in managing psoriasis. This article aims to comprehensively evaluate the anti-psoriatic activity, efficacy, and safety profiles of curcumin and its novel formulations, as well as to discuss future directions for enhancing their use as an alternative treatment for psoriasis. Curcumin exerts its anti-psoriatic effects through multi-targeted actions, including inhibiting cell proliferation, inducing apoptosis, suppressing pro-inflammatory cytokines, and enhancing skin barrier proteins, thereby alleviating psoriasis lesions. However, both oral and topical curcumin formulations face challenges, such as low bioavailability and limited skin penetration, underscoring the need for novel formulations to improve therapeutic outcomes. Clinical findings suggest that oral curcumin may provide greater efficacy and better tolerance as an adjunctive therapy for moderate to severe psoriasis, while topical formulations may help reduce severity and improve well-being in mild to moderate cases. Overall, curcumin and its novel formulations show promise as therapeutic agents for psoriasis treatment. However, further research, particularly large-scale clinical trials, is essential to evaluate long-term efficacy and safety comprehensively.